<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04368585</url>
  </required_header>
  <id_info>
    <org_study_id>SPR994-107</org_study_id>
    <nct_id>NCT04368585</nct_id>
  </id_info>
  <brief_title>Study to Examine the Effect of Antacid and Omeprazole on the Single-Dose Pharmacokinetics of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult Subjects</brief_title>
  <official_title>An Open-Label, 3-Period, Fixed-Sequence, Study to Examine the Effect of Aluminum Hydroxide/Magnesium Hydroxide/Simethicone and Omeprazole on the Single-Dose Pharmacokinetics of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spero Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spero Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the effect of a single dose of aluminum hydroxide/magnesium hydroxide/simethicone
      and omeprazole on the pharmacokinetics (PK) of TBPM, following a single dose of TBPM-PI-HBr
      in healthy adult subjects.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2020</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration-time curve, from time 0 to the last observed non-zero concentration (t).</measure>
    <time_frame>Day 2 (Periods 1 and 2) and Day 6 (Period 3)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve extrapolated to infinity (AUC0-∞).</measure>
    <time_frame>Day 2 (Periods 1 and 2) and Day 6 (Period 3)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of AUC0-inf extrapolated (AUC%extrap)</measure>
    <time_frame>Day 2 (Periods 1 and 2) and Day 6 (Period 3)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax).</measure>
    <time_frame>Day 2 (Periods 1 and 2) and Day 6 (Period 3)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to the maximum plasma concentration (Tmax).</measure>
    <time_frame>Day 2 (Periods 1 and 2) and Day 6 (Period 3)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal elimination half-life (t½).</measure>
    <time_frame>Day 2 (Periods 1 and 2) and Day 6 (Period 3)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent total body clearance (CL/F)</measure>
    <time_frame>Day 2 (Periods 1 and 2) and Day 6 (Period 3)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent volume of distribution during the terminal elimination phase after oral (extravascular) administration (Vz/F).</measure>
    <time_frame>Day 2 (Periods 1 and 2) and Day 6 (Period 3)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent AEs (including SAEs) categorized by severity and relationship to study drug.</measure>
    <time_frame>12 to 14 days after the last dose of study drug</time_frame>
    <description>ECG, Clinical Laboratories, Vitals Signs and Physical Exams will be used as a safety measure to detect any AEs.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>TBPM-PI-HBr Alone (Period 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) 600 mg single-dose given orally alone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TBPM-PI-HBr and Antacid (Period 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mL aluminum hydroxide/magnesium hydroxide/simethicone (400 mg aluminum hydroxide/400 mg magnesium hydroxide/40 mg simethicone per 5 mL) oral suspension will be coadministered with 600 mg (2 x 300 mg tablets) TBPM-PI-HBr at Hour 0 on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TBPM-PI-HBr and Omeprazole (Period 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 mg (1 x 40 mg capsule) omeprazole administered QD at Hour -2 on Days 1 through 5, with 600 mg (2 x 300 mg tablets) TBPM-PI-HBr administered at Hour 0 on Day 5.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)</intervention_name>
    <description>Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) 600 mg single-dose given orally.</description>
    <arm_group_label>TBPM-PI-HBr Alone (Period 1)</arm_group_label>
    <arm_group_label>TBPM-PI-HBr and Antacid (Period 2)</arm_group_label>
    <arm_group_label>TBPM-PI-HBr and Omeprazole (Period 3)</arm_group_label>
    <other_name>TBPM-PI-HBr</other_name>
    <other_name>SPR994</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>20 mL aluminum hydroxide/magnesium hydroxide/simethicone (400 mg aluminum hydroxide/400 mg magnesium hydroxide/40 mg simethicone per 5 mL)</intervention_name>
    <description>20 mL aluminum hydroxide/magnesium hydroxide/simethicone (400 mg aluminum hydroxide/400 mg magnesium hydroxide/40 mg simethicone per 5 mL) oral suspension.</description>
    <arm_group_label>TBPM-PI-HBr and Antacid (Period 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omeprazole</intervention_name>
    <description>40 mg (1 x 40 mg capsule) omeprazole administered QD</description>
    <arm_group_label>TBPM-PI-HBr and Omeprazole (Period 3)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Healthy, adult, male or female, 18-55 years of age, inclusive, at the screening visit.

          -  Continuous non-smoker

          -  Body mass index (BMI) ≥ 18.0 and ≤ 32.0 kg/m2 at the screening visit.

          -  Medically healthy with no clinically significant medical history, physical
             examination, laboratory profiles, vital signs or ECGs, as deemed by the PI or
             designee.

        Key Exclusion Criteria:

          -  Is mentally or legally incapacitated or has significant emotional problems at the time
             of the screening visit or expected to have during the conduct of the study.

          -  History or presence of clinically significant medical or psychiatric condition or
             disease in the opinion of the PI or designee.

          -  History of any illness that, in the opinion of the PI or designee, might confound the
             results of the study or poses an additional risk to the subject by their participation
             in the study.

          -  History of significant allergic disease requiring treatment

          -  History or presence of alcoholism or drug abuse within the past 2 years prior to the
             first dose.

          -  History or presence of hypersensitivity or idiosyncratic reaction to the study drugs
             or related compounds (especially fluoroquinolone-, carbapenem-, penicillin-, and
             cephalosporin-antibiotics sensitivity).

          -  History of known genetic metabolism anomaly associated with carnitine deficiency
             (e.g., carnitine transporter defect, methylmalonic aciduria, propionic acidemia).

          -  History of cholecystectomy.

          -  Female subjects with a positive pregnancy test at the screening visit or first
             check-in or who are lactating.

          -  Positive urine drug or alcohol results at the screening visit or first check-in.

          -  Positive results at the screening visit for human immunodeficiency virus (HIV 1 and
             2), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Melnick, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Spero Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Floni Bajraktari</last_name>
    <phone>+1 (857) 242-1557</phone>
    <email>fbajraktari@sperotherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 9, 2020</study_first_submitted>
  <study_first_submitted_qc>April 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2020</study_first_posted>
  <last_update_submitted>April 27, 2020</last_update_submitted>
  <last_update_submitted_qc>April 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simethicone</mesh_term>
    <mesh_term>Omeprazole</mesh_term>
    <mesh_term>Aluminum Hydroxide</mesh_term>
    <mesh_term>Magnesium Hydroxide</mesh_term>
    <mesh_term>Aluminum hydroxide, magnesium hydroxide, simethicone drug combination</mesh_term>
    <mesh_term>Aluminum hydroxide, magnesium hydroxide, drug combination</mesh_term>
    <mesh_term>TEMPO</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

